Hengrui Medicine (600276.SH): Clinical trials of multiple drugs including SHR-9839(sc) for injection approved.

Zhtng Cijng APP news, Hng Ru Yyo (600276.SH) issued an announcement recently. The company and its subsidiaries, Suzhou Shngdy Shngw Yyo Yuxin Gngs, Shanghai Hng Ru Yyo Yuxin Gngs, and Shanghai Shngd Yyo Yuxin Gngs, have received the Drug Administration Approval Letter for Clinical Trials of Injection SHR-9839(sc), Injection SHR-A2009, Injection SHR-1826, HRS-4642 Injection, Adelbil Monoclonal Antibody Injection, Injection Rui Kng Qtu Zhn Monoclonal Antibody, Injection SHR-A2102, HRS-7058 Capsules, and HRS-7058 Tablets from the National Medical Products Administration (referred to as "NMPA"), and will soon begin clinical trials. Specifically, a phase IB/II study protocol on the safety, tolerability, and efficacy of injection SHR-9839(sc) in combination with anti-tumor drugs in solid tumor subjects will be conducted.